Neuroprotective Therapy for Stroke and Ischemic Disease

1. Front Matter

   Pages i-xvii

   PDF

2. Stroke Neuroprotection: The History and Learning Experience

   1. Front Matter

      Pages 1-1

      PDF

   2. Reflections on Neuroprotection Research and the Path Toward Clinical Success

      • Paul A. Lapchak, Paul D. Boitano

      Pages 3-71

   3. Systematic Review and Meta-analysis: Important Tools in Understanding Drug Development for Stroke

      • Sarah K. McCann, Emily S. Sena, Gillian L. Currie, Malcolm R. Macleod, David W. Howells

      Pages 73-93

   4. Neuroprotection Is Technology, Not Science

      • Donald J. DeGracia, Doaa Taha, Fika Tri Anggraini, Zhifeng Huang

      Pages 95-122

   5. History of Experimental Stroke Research

      • Victoria E. O’Collins

      Pages 123-131

   6. History of Neuroprotection: Trials and Tribulations

      • Ali Razmara, Steven C. Cramer

      Pages 133-154

3. Novel Neuroprotection Mechanisms and Targets

   1. Front Matter

      Pages 155-155

      PDF

   2. Targeting PSD-95 as a Novel Approach in the Treatment of Stroke

      • Linda M. Haugaard-Kedström, Eduardo F. A. Fernandes, Kristian Strømgaard

      Pages 157-184

   3. ATP-Sensitive Potassium Channels (KATP) Play a Role in Hypoxic Preconditioning Against Neonatal Hypoxic-Ischemic Brain Injury

      • Zhong-Ping Feng, Hong-Shuo Sun

      Pages 185-201

   4. Targeting Oxidative Stress in Stroke

      • Anders Bach

      Pages 203-250

   5. Nitrones, Old Fellows for New Therapies in Ischemic Stroke

      • Alejandro Escobar-Peso, Mourad Chioua, Valerio Frezza, Emma Martínez-Alonso, José Marco-Contelles, Alberto Alcázar

      Pages 251-283

   6. Neuroprotective Strategies via Modulation of Innate Immune Receptors

      • George Trendelenburg

      Pages 285-292

   7. Harnessing the Power of the Human Immune System via Multi-omic Immune Profiling in Stroke Treatment and Recovery

      • Taura L. Barr, V. Gionis, R. Giersch

      Pages 293-301

   8. Polarization of Microglia/Macrophages in Brain Ischaemia: Relevance for Stroke Therapy

      • Diana Amantea, Rosaria Greco, Cristina Tassorelli, Giacinto Bagetta

      Pages 303-328

   9. Endoplasmic Reticulum Stress: An Opportunity for Neuroprotective Strategies After Stroke

      • Morgane Louessard, Eloise Lemarchand, Carine Ali, Denis Vivien, Benoit Denis Roussel

      Pages 329-348

   10. Effects of Neuroprotectants Before and After Stroke: Statins and Anti-hypertensives

       • Roberto Federico Villa, Federica Ferrari, Antonio Moretti

       Pages 349-399

   11. Toward Effective Combination Therapy and Pleiotropic Drugs

       • Sergio Amaro, Xabier Urra, Ángel Chamorro

       Pages 401-414

   12. TRPM7 Channels as Potential Therapeutic Targets for Stroke

       • Hong-Shuo Sun, Zhong-Ping Feng

       Pages 415-432

   13. Cholinergic Protection in Ischemic Brain Injury

       • Victor V. Uteshev

       Pages 433-457

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.

• CNS disorders
• thrombolysis
• oxidative stress
• excitotoxicity
• sex-specific

• Department of Neurology and Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, USA

  Paul A. Lapchak

• Loma Linda University School of Medicine, Loma Linda, USA

  John H. Zhang

Paul Lapchak is the director of translational neurodegenerative disease research at Cedars-Sinai Medical Center in California. Dr. Lapchak obtained his Ph.D. at McGill University and University of Southern California. His lab focuses on developing new therapeutic approaches to treat different types of stroke as well as experimenting with neuroprotective agents. In addition, his research extends to drug development using the rabbit embolic stroke model and multiple assay methods. Dr. Lapchak is editor-in-chief of the Journal of Neurology & Neurophysiology and associate editor of the journal Translational Stroke Research. With over twenty years of experience and numerous publications, Dr. Lapchak is a leading expert in his field of translational stroke research.

John Zhang is doctor and professor in the departments of Anesthesiology, Neurosurgery, Neurology, and Physiology at the Loma Linda University School of Medicine in California. He obtained his Ph.D. at the University of Alberta, Canada and his MD at Chongqing University of Medical Sciences, China. His lab focuses on hemorrhagic and ischemic stroke, specifically on cerebral vascular biology, neuroprotection, gene therapy, signaling pathways, and apoptosis. Dr. Zhang is on the editorial boards of the journals Surgical Neurology and Neurological Research. Coauthor of countless publications, Dr. Zhang is also a member of several professional societies and participates in current discussions of stroke disease research and neuroprotection.

Policies and ethics